Published in Nat Med on July 01, 2000
Dengue: a continuing global threat. Nat Rev Microbiol (2010) 9.96
Dengue: an escalating problem. BMJ (2002) 6.09
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev (2009) 3.61
Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol (2005) 3.58
Microevolution and virulence of dengue viruses. Adv Virus Res (2003) 3.41
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep (2003) 3.29
Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol (2004) 2.83
Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol (2006) 2.76
Development and evaluation of serotype- and group-specific fluorogenic reverse transcriptase PCR (TaqMan) assays for dengue virus. J Clin Microbiol (2001) 2.75
Dengue: defining protective versus pathologic immunity. J Clin Invest (2004) 2.73
Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol (2005) 2.50
Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol (2005) 2.44
Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol (2005) 2.37
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol (2014) 2.34
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti. Am J Trop Med Hyg (2003) 2.16
Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J Clin Invest (2004) 2.11
American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol (2003) 2.03
The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe (2012) 2.03
Dengue fever in humanized NOD/SCID mice. J Virol (2005) 1.96
Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol (2001) 1.92
Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis (2007) 1.86
Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med (2010) 1.86
Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol (2006) 1.84
An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol (2004) 1.81
DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog (2012) 1.80
Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med (2000) 1.80
Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J Exp Med (2001) 1.79
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J Virol (2001) 1.74
A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A (2006) 1.72
Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. J Clin Microbiol (2002) 1.71
Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol (2008) 1.65
Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol (2004) 1.65
Dengue virus evolution and virulence models. Clin Infect Dis (2007) 1.64
Differential induction of type I interferon responses in myeloid dendritic cells by mosquito and mammalian-cell-derived alphaviruses. J Virol (2006) 1.57
Mouse models of dengue virus infection and disease. Antiviral Res (2008) 1.56
Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology (2008) 1.54
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology (2006) 1.49
Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells. J Virol (2007) 1.48
Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol (2010) 1.45
Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol Cell Biol (2005) 1.45
Replication in cells of hematopoietic origin is necessary for Dengue virus dissemination. PLoS Pathog (2012) 1.44
Retracted Recent advances in DENV receptors. ScientificWorldJournal (2013) 1.43
Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol (2010) 1.42
Dengue viruses - an overview. Infect Ecol Epidemiol (2013) 1.40
Study of sequence variation of dengue type 3 virus in naturally infected mosquitoes and human hosts: implications for transmission and evolution. J Virol (2004) 1.37
Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol (2012) 1.36
Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol (2006) 1.34
Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J Virol (2001) 1.33
Differential effects of dengue virus on infected and bystander dendritic cells. J Virol (2005) 1.33
A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg (2012) 1.31
Keratinocytes are cell targets of West Nile virus in vivo. J Virol (2011) 1.29
Innate immunity evasion by Dengue virus. Viruses (2012) 1.29
Enhancement by tumor necrosis factor alpha of dengue virus-induced endothelial cell production of reactive nitrogen and oxygen species is key to hemorrhage development. J Virol (2008) 1.27
Progress on the development of therapeutics against West Nile virus. Antiviral Res (2009) 1.26
Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol (2005) 1.26
Zika Virus Targets Different Primary Human Placental Cells, Suggesting Two Routes for Vertical Transmission. Cell Host Microbe (2016) 1.24
Flavivirus entry receptors: an update. Viruses (2013) 1.23
Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol (2010) 1.23
How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol (2010) 1.23
Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe (2014) 1.22
Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol (2007) 1.20
Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice. J Virol (2012) 1.18
Hantavirus infection of dendritic cells. J Virol (2002) 1.18
TRAIL is a novel antiviral protein against dengue virus. J Virol (2007) 1.17
Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol (2013) 1.17
Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein. J Virol (2003) 1.16
Dengue virus virulence and transmission determinants. Curr Top Microbiol Immunol (2010) 1.15
Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells. Int J Exp Pathol (2005) 1.15
Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. PLoS Negl Trop Dis (2012) 1.14
Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol (2002) 1.14
Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression. Virology (2004) 1.13
Epitope-blocking enzyme-linked immunosorbent assay to differentiate west nile virus from Japanese encephalitis virus infections in equine sera. Clin Vaccine Immunol (2007) 1.13
Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J Virol (2005) 1.11
Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. Elife (2013) 1.10
Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. J Leukoc Biol (2008) 1.09
Dengue virus and dendritic cells. Nat Med (2000) 1.08
Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells. PLoS Pathog (2014) 1.07
Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol (2009) 1.06
Mosquito saliva serine protease enhances dissemination of dengue virus into the mammalian host. J Virol (2013) 1.05
Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol (2007) 1.05
Both E protein glycans adversely affect dengue virus infectivity but are beneficial for virion release. J Virol (2010) 1.05
Inducible nitric oxide synthase (iNOS) expression in monocytes during acute Dengue Fever in patients and during in vitro infection. BMC Infect Dis (2005) 1.03
S-phase-dependent enhancement of dengue virus 2 replication in mosquito cells, but not in human cells. J Virol (2005) 1.03
Viral pathogenesis in mice is similar for West Nile virus derived from mosquito and mammalian cells. Virology (2010) 1.03
West Nile virus: immunity and pathogenesis. Viruses (2011) 1.02
Ross River virus envelope glycans contribute to type I interferon production in myeloid dendritic cells. J Virol (2008) 1.02
Detection of dengue viral RNA using a nucleic acid sequence-based amplification assay. J Clin Microbiol (2001) 1.02
Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front Immunol (2014) 1.01
Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection. PLoS Pathog (2014) 1.01
Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PLoS One (2011) 1.01
Dendritic cells: immune saviors or Achilles' heel? Infect Immun (2001) 0.98
A role for the JAK-STAT1 pathway in blocking replication of HSV-1 in dendritic cells and macrophages. Virol J (2009) 0.97
Dermal-type macrophages expressing CD209/DC-SIGN show inherent resistance to dengue virus growth. PLoS Negl Trop Dis (2008) 0.97
N-linked glycans on dengue viruses grown in mammalian and insect cells. J Gen Virol (2009) 0.97
Tick-borne flaviviruses: dissecting host immune responses and virus countermeasures. Immunol Res (2009) 0.97
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11
X-ray structure determination of fully hydrated L alpha phase dipalmitoylphosphatidylcholine bilayers. Biophys J (1996) 5.60
The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med (1997) 5.23
A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 4.23
Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet (1999) 3.97
Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med (2007) 3.75
Sodium channel mutations in paramyotonia congenita uncouple inactivation from activation. Neuron (1994) 3.67
Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med (1997) 3.55
A nanomechanical device based on the B-Z transition of DNA. Nature (1999) 3.43
Borrelia burgdorferi genes selectively expressed in the infected host. Proc Natl Acad Sci U S A (1995) 3.42
Detection of diverse HIV-1 genetic subtypes in the USA. Lancet (1995) 3.41
The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med (1997) 3.36
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science (2001) 3.22
HIV-1 suppression during acute scrub-typhus infection. Lancet (2000) 3.08
Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem (1992) 2.97
A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996. Am J Trop Med Hyg (1999) 2.78
Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology (1998) 2.76
Development and evaluation of serotype- and group-specific fluorogenic reverse transcriptase PCR (TaqMan) assays for dengue virus. J Clin Microbiol (2001) 2.75
Catheter-associated sepsis caused by Ochrobactrum anthropi: report of a case and review of related nonfermentative bacteria. Clin Infect Dis (1992) 2.70
Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol (1999) 2.68
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med (1993) 2.61
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol (2006) 2.57
Respiratory hospital admissions and summertime haze air pollution in Toronto, Ontario: consideration of the role of acid aerosols. Environ Res (1994) 2.47
Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. Immunity (1997) 2.38
Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg (2001) 2.35
Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol (1985) 2.31
Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1995) 2.23
Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo. Cell (1998) 2.21
In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol (1998) 2.09
Detection of West Nile virus by the polymerase chain reaction and analysis of nucleotide sequence variation. Am J Trop Med Hyg (1993) 2.07
Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-alpha transcription factors. Proc Natl Acad Sci U S A (1997) 2.06
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Detection of Shigellae and enteroinvasive Escherichia coli by amplification of the invasion plasmid antigen H DNA sequence in patients with dysentery. J Infect Dis (1993) 1.97
Human dendritic cells as targets of dengue virus infection. J Investig Dermatol Symp Proc (2001) 1.96
Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. Clin Infect Dis (1999) 1.93
Cloning of the gene encoding the 44-kilodalton antigen of the agent of human granulocytic ehrlichiosis and characterization of the humoral response. Infect Immun (1998) 1.92
Dendritic cells capable of stimulating T cells in germinal centres. Nature (1996) 1.90
Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol (1999) 1.88
Small-angle x-ray scattering from lipid bilayers is well described by modified Caillé theory but not by paracrystalline theory. Biophys J (1996) 1.87
Vertical transmission of West Nile virus by Culex and Aedes species mosquitoes. Am J Trop Med Hyg (1993) 1.86
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83
Isolation and characterization of RNA from low-biomass deep-subsurface sediments. Appl Environ Microbiol (1995) 1.82
Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992-1993. Am J Trop Med Hyg (1995) 1.81
Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med (2000) 1.80
Dominant negative umuD mutations decreasing RecA-mediated cleavage suggest roles for intact UmuD in modulation of SOS mutagenesis. Proc Natl Acad Sci U S A (1990) 1.79
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine (2001) 1.79
Evaluation of a dipstick enzyme-linked immunosorbent assay for detection of antibodies to dengue virus. Clin Diagn Lab Immunol (1997) 1.78
Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage (2010) 1.75
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol (1996) 1.75
Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol (1997) 1.72
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
Changing association between community occupational structure and ischaemic heart disease mortality in the United States. Lancet (1987) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Pyogenic infections due to Ochrobactrum anthropi. Clin Infect Dis (1996) 1.66
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. AIDS (1997) 1.65
Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys (2000) 1.64
Impaired motor coordination and persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking Galphaq. Proc Natl Acad Sci U S A (1997) 1.62
Composition and functional analysis of the Saccharomyces cerevisiae trehalose synthase complex. J Biol Chem (1998) 1.60
Panel studies of acute health effects of air pollution. I. Cardiopulmonary symptoms in adults, New York, 1971-1972. Environ Res (1976) 1.60
Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys (1993) 1.59
Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis (1995) 1.58
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol (1996) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J Infect Dis (1999) 1.54
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS (2000) 1.53
Assembly of Borromean rings from DNA. Nature (1997) 1.51
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol (1998) 1.51
Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol (1995) 1.50
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol (2001) 1.50
Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration. Br J Ophthalmol (2008) 1.49
Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis (1999) 1.49
Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med (1999) 1.48